Cargando…

The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial

OBJECTIVES: In general populations, the adverse effects of smoking on coronary risk have been demonstrated to be greater in women than in men; whether this is true for individuals with diabetes is unclear. DESIGN: Cohort study. SETTING: 20 countries worldwide participating in the ADVANCE (Action in...

Descripción completa

Detalles Bibliográficos
Autores principales: Blomster, Juuso I, Woodward, Mark, Zoungas, Sophia, Hillis, Graham S, Harrap, Stephen, Neal, Bruce, Poulter, Neil, Mancia, Giuseppe, Chalmers, John, Huxley, Rachel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716176/
https://www.ncbi.nlm.nih.gov/pubmed/26747037
http://dx.doi.org/10.1136/bmjopen-2015-009668
_version_ 1782410516043399168
author Blomster, Juuso I
Woodward, Mark
Zoungas, Sophia
Hillis, Graham S
Harrap, Stephen
Neal, Bruce
Poulter, Neil
Mancia, Giuseppe
Chalmers, John
Huxley, Rachel
author_facet Blomster, Juuso I
Woodward, Mark
Zoungas, Sophia
Hillis, Graham S
Harrap, Stephen
Neal, Bruce
Poulter, Neil
Mancia, Giuseppe
Chalmers, John
Huxley, Rachel
author_sort Blomster, Juuso I
collection PubMed
description OBJECTIVES: In general populations, the adverse effects of smoking on coronary risk have been demonstrated to be greater in women than in men; whether this is true for individuals with diabetes is unclear. DESIGN: Cohort study. SETTING: 20 countries worldwide participating in the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial. PARTICIPANTS: 11 140 patients with type 2 diabetes aged ≥55 years and in cardiovascular risk at the time of randomisation. PRIMARY AND SECONDARY OUTCOME MEASURES: Major cardiovascular events (death from cardiovascular disease, non-fatal stroke or non-fatal myocardial infarction (MI)), all cardiovascular events (major cardiovascular event or peripheral arterial disease or transient ischaemic attack), and all-cause mortality. Secondary outcome measures were major coronary events (fatal and non-fatal MI), major cerebrovascular events (fatal and non-fatal stroke), nephropathy (new or worsening renal disease), and all cancer. RESULTS: At baseline, 6466 (56% women) participants were never-smokers, 1550 (28% women) were daily smokers and 3124 (21% women) were former smokers. Median follow-up time was 5 years. In Cox regression models after multiple adjustments, compared with never smoking, daily smoking was associated with increased risk of all primary and secondary outcomes with the exception of major cerebrovascular disease. Only for major coronary events was there any evidence of a stronger effect in women than in men (ratio of the adjusted HRs women:men; 1.64 (0.83 to 3.26) p=0.08). For all other outcomes considered, the hazards of smoking were similar in men and women. Quitting smoking was associated with a 30% reduction in all-cause mortality (p=0.001) in both sexes. CONCLUSIONS: In individuals with diabetes, the effects of smoking on all major forms of cardiovascular disease are equally as hazardous in women and men with the possible exception of major coronary events where there was some evidence of a greater hazard in women. TRIAL REGISTRATION NUMBER: NCT00145925.
format Online
Article
Text
id pubmed-4716176
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-47161762016-01-31 The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial Blomster, Juuso I Woodward, Mark Zoungas, Sophia Hillis, Graham S Harrap, Stephen Neal, Bruce Poulter, Neil Mancia, Giuseppe Chalmers, John Huxley, Rachel BMJ Open Smoking and Tobacco OBJECTIVES: In general populations, the adverse effects of smoking on coronary risk have been demonstrated to be greater in women than in men; whether this is true for individuals with diabetes is unclear. DESIGN: Cohort study. SETTING: 20 countries worldwide participating in the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial. PARTICIPANTS: 11 140 patients with type 2 diabetes aged ≥55 years and in cardiovascular risk at the time of randomisation. PRIMARY AND SECONDARY OUTCOME MEASURES: Major cardiovascular events (death from cardiovascular disease, non-fatal stroke or non-fatal myocardial infarction (MI)), all cardiovascular events (major cardiovascular event or peripheral arterial disease or transient ischaemic attack), and all-cause mortality. Secondary outcome measures were major coronary events (fatal and non-fatal MI), major cerebrovascular events (fatal and non-fatal stroke), nephropathy (new or worsening renal disease), and all cancer. RESULTS: At baseline, 6466 (56% women) participants were never-smokers, 1550 (28% women) were daily smokers and 3124 (21% women) were former smokers. Median follow-up time was 5 years. In Cox regression models after multiple adjustments, compared with never smoking, daily smoking was associated with increased risk of all primary and secondary outcomes with the exception of major cerebrovascular disease. Only for major coronary events was there any evidence of a stronger effect in women than in men (ratio of the adjusted HRs women:men; 1.64 (0.83 to 3.26) p=0.08). For all other outcomes considered, the hazards of smoking were similar in men and women. Quitting smoking was associated with a 30% reduction in all-cause mortality (p=0.001) in both sexes. CONCLUSIONS: In individuals with diabetes, the effects of smoking on all major forms of cardiovascular disease are equally as hazardous in women and men with the possible exception of major coronary events where there was some evidence of a greater hazard in women. TRIAL REGISTRATION NUMBER: NCT00145925. BMJ Publishing Group 2016-01-08 /pmc/articles/PMC4716176/ /pubmed/26747037 http://dx.doi.org/10.1136/bmjopen-2015-009668 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Smoking and Tobacco
Blomster, Juuso I
Woodward, Mark
Zoungas, Sophia
Hillis, Graham S
Harrap, Stephen
Neal, Bruce
Poulter, Neil
Mancia, Giuseppe
Chalmers, John
Huxley, Rachel
The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial
title The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial
title_full The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial
title_fullStr The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial
title_full_unstemmed The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial
title_short The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial
title_sort harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the advance (action in diabetes and vascular disease: preterax and diamicron modified release controlled evaluation) trial
topic Smoking and Tobacco
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716176/
https://www.ncbi.nlm.nih.gov/pubmed/26747037
http://dx.doi.org/10.1136/bmjopen-2015-009668
work_keys_str_mv AT blomsterjuusoi theharmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial
AT woodwardmark theharmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial
AT zoungassophia theharmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial
AT hillisgrahams theharmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial
AT harrapstephen theharmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial
AT nealbruce theharmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial
AT poulterneil theharmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial
AT manciagiuseppe theharmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial
AT chalmersjohn theharmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial
AT huxleyrachel theharmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial
AT blomsterjuusoi harmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial
AT woodwardmark harmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial
AT zoungassophia harmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial
AT hillisgrahams harmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial
AT harrapstephen harmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial
AT nealbruce harmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial
AT poulterneil harmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial
AT manciagiuseppe harmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial
AT chalmersjohn harmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial
AT huxleyrachel harmsofsmokingandbenefitsofsmokingcessationinwomencomparedwithmenwithtype2diabetesanobservationalanalysisoftheadvanceactionindiabetesandvasculardiseasepreteraxanddiamicronmodifiedreleasecontrolledevaluationtrial